These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 17661794

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients.
    Vallittu AM, Peltoniemi J, Elovaara I, Kuusisto H, Färkkilä M, Multanen J, Erälinna JP.
    Acta Neurol Scand; 2005 Oct; 112(4):234-7. PubMed ID: 16146492
    [Abstract] [Full Text] [Related]

  • 5. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [Abstract] [Full Text] [Related]

  • 6. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T.
    Mult Scler; 2009 Aug 01; 15(8):959-64. PubMed ID: 19667022
    [Abstract] [Full Text] [Related]

  • 16. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E.
    Int J Clin Pract Suppl; 2002 Sep 01; (131):3-7. PubMed ID: 12564806
    [Abstract] [Full Text] [Related]

  • 17. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb 01; 13(69):10-2. PubMed ID: 15055208
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.